Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
Type 2 inflammation driven by elevated IL-4, IL-5, and IL-13 links nasal polyps with asthma by promoting eosinophil activation, mucus overproduction, and tissue remodeling in both the sinuses and airways.
There are several factors to consider, including genetic predisposition, allergen exposure, and targeted treatments like biologics and corticosteroids. See below for more details that could impact which next steps you take in your healthcare journey.
Nasal polyps—soft, noncancerous growths in the lining of the nose or sinuses—often occur alongside asthma. If you've ever wondered why do nasal polyps go hand in hand with asthma, you're not alone. Both conditions share underlying inflammatory processes driven by similar immune signals, called cytokines. Understanding this connection helps explain symptoms, guide treatment, and highlight the importance of early evaluation.
Nasal Polyps
• Small, grape-like swellings in the nasal passages or sinuses
• Can cause congestion, runny nose, loss of smell, and facial pressure
• Often develop in people with chronic sinusitis or allergies
Asthma
• A chronic lung condition marked by airway inflammation and constriction
• Symptoms include wheezing, shortness of breath, chest tightness, and coughing
• Triggers range from allergens and exercise to respiratory infections
Despite affecting different parts of the respiratory tract, both conditions frequently co-exist. Research shows up to 40% of people with nasal polyps also have asthma, and vice versa.
Central to both nasal polyps and asthma is Type 2 inflammation, an immune response characterized by elevated levels of specific cytokines—small proteins that coordinate cell activity.
Key Type 2 cytokines:
Interleukin-4 (IL-4)
• Promotes antibody (IgE) production by B cells
• Drives allergic reactions
Interleukin-5 (IL-5)
• Stimulates growth and activation of eosinophils (a type of white blood cell)
• Eosinophils release toxic granules that damage airway and nasal tissues
Interleukin-13 (IL-13)
• Increases mucus production
• Contributes to airway hyperresponsiveness and polyp growth
When these cytokines are overproduced:
Eosinophil Recruitment
• IL-5 drives eosinophil maturation in bone marrow
• Eosinophils migrate to airways and nasal tissues
• Their granules damage epithelial cells, perpetuating inflammation
Goblet Cell Metaplasia
• IL-13 triggers nasal and airway epithelial cells to become mucus-secreting goblet cells
• Excess mucus worsens obstruction in sinuses and bronchi
T Helper 2 (Th2) Cell Activation
• Th2 cells are a subset of T lymphocytes primed by allergens or pollutants
• They release IL-4, IL-5, and IL-13, amplifying Type 2 inflammation
Barrier Dysfunction
• Inflammation weakens the epithelial barrier in nasal passages and airways
• Makes it easier for allergens and microbes to penetrate, fueling chronic symptoms
This cycle of immune activation and tissue damage underlies both polyp formation and asthma exacerbations.
While Type 2 inflammation is the core link, other factors influence why nasal polyps go hand in hand with asthma:
Genetic Predisposition
• Variants in genes related to IL-4, IL-5, and IL-13 signaling
• Family history of atopy (allergic diseases) increases risk
Allergen Exposure
• Pollen, dust mites, animal dander, and molds can trigger Th2 responses
• Chronic exposure sustains inflammation in nose and lungs
Infections
• Repeated viral or bacterial infections can exacerbate both conditions
• May promote polyp growth and asthma flare-ups
Aspirin-Exacerbated Respiratory Disease (AERD)
• A subset of patients react to aspirin or NSAIDs with worsening asthma and rapid polyp development
Understanding the shared cytokine pathways helps guide effective treatment:
Biologics
• Monoclonal antibodies against IL-5 (e.g., mepolizumab, reslizumab)
• Anti-IL-4/IL-13 agents (e.g., dupilumab)
• Shown to reduce polyp size and improve asthma control
Intranasal Corticosteroids
• First-line for reducing nasal inflammation and shrinking polyps
• Lower systemic side effects compared to oral steroids
Inhaled Corticosteroids and Bronchodilators
• Mainstay for asthma to reduce airway inflammation and open airways
Nasal Saline Irrigation
• Flushes allergens and thick mucus from sinuses
• Can improve breathing and reduce polyp irritation
Avoidance of Triggers
• Identify and minimize exposure to allergens, smoke, and pollutants
• Especially important in those with aspirin sensitivity
Surgery
• Functional endoscopic sinus surgery (FESS) may be needed for large or persistent polyps
• Often combined with ongoing medical therapy to prevent recurrence
Recognizing symptoms early can slow disease progression and improve quality of life:
Prompt evaluation by a healthcare provider ensures timely diagnosis and a tailored treatment plan.
If you suspect you have nasal polyps, asthma, or both, schedule an appointment. Your doctor may recommend:
Together, you can discuss the best combination of therapies to control inflammation and keep symptoms at bay.
Nasal polyps and asthma are closely intertwined through Type 2 inflammation and shared cytokine pathways. Elevated levels of IL-4, IL-5, and IL-13 drive eosinophil activation, mucus overproduction, and tissue changes in both the nose and lungs. Genetic factors, allergen exposure, and certain medications can further tip the balance toward chronic inflammation. Recognizing this cellular link not only explains why do nasal polyps go hand in hand with asthma but also paves the way for targeted treatments, from corticosteroids to biologic therapies. If you have persistent nasal or respiratory symptoms, don't wait—talk to your doctor about evaluation and management, and consider taking a moment to use Ubie's free Bronchial Asthma symptom checker to better understand your respiratory health before your appointment. Always seek medical advice for anything that could be serious or life-threatening.
(References)
* Bachert C, Zhang N. Type 2 Inflammation in Chronic Rhinosinusitis With Nasal Polyps and Asthma. Front Allergy. 2022 Mar 22;3:858661. doi: 10.3389/falgy.2022.858661. PMID: 35386401.
* Bachert C, Sousa AR, Pfaar O, Lourenço O. The molecular connection between nasal polyps and asthma. Curr Opin Allergy Clin Immunol. 2021 Feb;21(1):21-26. doi: 10.1097/ACI.0000000000000713. PMID: 33264103.
* Hellings PW, Seys SF, Proenca C, Wróbel P, Gevaert P, Bachert C. CRSwNP with comorbid asthma: Molecular insights and emerging therapies. J Allergy Clin Immunol. 2021 Mar;147(3):805-812. doi: 10.1016/j.jaci.2020.12.646. PMID: 33444983.
* D'Ambrosio C, Cingi C, Pfaar O. The role of type 2 inflammation in the pathogenesis of chronic rhinosinusitis with nasal polyps. Rhinology. 2020 Dec 1;58(6):507-515. doi: 10.4193/Rhin20.082. PMID: 33306443.
* Cho YK, Min YK, Oh S. Interleukin-33 (IL-33) in Chronic Rhinosinusitis with Nasal Polyps and Asthma Comorbidity: A Review of Pathophysiology and Clinical Implications. J Asthma Allergy. 2023 Dec 15;16:305-316. doi: 10.2147/JAA.S440957. PMID: 38125442.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.